The identity refresh positions Zydus Wellness as an organization rooted in science, driven by compassion, and inspired by the ...

Zydus Lifesciences is on analysts' radar. The stock rose nearly 2% on Wednesday after reporting mixed fourth-quarter results.

After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

ICICI Securities recommended hold rating on Zydus Lifesciences with a target price of Rs 910 in its research report dated May ...

We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a ...

Pearl Global, Gillette India, and three other stocks surged the most in the last five days. (Image: Mata Ai) The Indian ...

The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

Ahmedabad-based Zydus Lifesciences Ltd has registered a decline of around 1% in net profit at Rs. 1,170.9 crore during the last quarter of FY25, as compared to Rs. 1,182.3 crore in the same period a ...

The 30-share BSE Sensex was up 593.84 points at 81780.28 ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Zydus Lifesciences Ltd. reported growth in the fourth quarter of fiscal 2025, driven by higher non-recurring components in ...

Nomura recommends Infosys as a top pick, emphasizing its focus on cash flow and disciplined M&A approach. CLSA has an ...